The Role of Citrullination in Inflammatory Bowel Disease: A Neglected Player in Triggering Inflammation and Fibrosis?

abstract：SUMMARY:: In recent years, heparin has emerged as a possible therapy for inflammatory bowel disease (IBD). Several recent, strongly positive, open-labeled series of heparin in both ulcerative colitis (UC) and Crohn's disease (CD) reinforce the work of Gaffney and co-workers that suggested a benefit of heparin in UC. Al...

journal_title：Inflammatory bowel diseases

authors： Korzenik JR

更新日期：1997-07-01 00:00:00

abstract：:Corticosteroids, and more recently biologics, have been the mainstay of therapy for patients with inflammatory bowel disease. Unfortunately, both are fraught with side effects and limited by lack of efficacy or loss of response. Many patients ultimately succumb to medically refractory disease and require an operation....

journal_title：Inflammatory bowel diseases

authors： Lightner AL

更新日期：2018-07-12 00:00:00

abstract：BACKGROUND:Ulcerative colitis (UC) negatively affects health-related quality of life (HRQoL), but population-based and long-term data on this topic are scarce. Our aim was to determine the HRQoL in UC patients after a 10-year disease duration. METHODS:UC patients from a population-based inception cohort met at a presc...

journal_title：Inflammatory bowel diseases

authors： Hoivik ML,Moum B,Solberg IC,Cvancarova M,Hoie O,Vatn MH,Bernklev T,IBSEN Study Group.

更新日期：2012-08-01 00:00:00

abstract：BACKGROUND:Inflammatory bowel disease (IBD) patients have a high incidence of wound and overall postoperative complications. A totally laparoscopic approach could potentially reduce these risks. We adopted totally laparoscopic total proctocolectomy (TL-TPC) using the perineal wound for extraction as the procedure of ch...

journal_title：Inflammatory bowel diseases

authors： Holder-Murray J,Zoccali M,Hurst RD,Umanskiy K,Rubin M,Fichera A

更新日期：2012-05-01 00:00:00

abstract：BACKGROUND:The pathophysiological basis for corticosteroid (CS) failure in ulcerative colitis (UC) is unknown. A transactivation glucocorticoid bioassay (GBA) was developed to measure the biological activity of CS by quantifying glucocorticoid response elements. This approach eliminates differences in bioavailability, ...

journal_title：Inflammatory bowel diseases

authors： Turner D,Kolho KL,Mack DR,Raivio T,Leleiko N,Crandall W,Markowitz J,Silverberg MS,Jänne OA,Stempak J,Hyams J,Griffiths AM

更新日期：2010-03-01 00:00:00

abstract：BACKGROUND:Up to 20% of patients with ulcerative colitis (UC) become steroid-dependent during their course. Thiopurines are recommended in steroid-dependent UC, but their efficacy is debated. Data exploring the use of infliximab in these patients are scarce. Aims of this study were to evaluate the effectiveness of infl...

journal_title：Inflammatory bowel diseases

authors： Armuzzi A,Pugliese D,Danese S,Rizzo G,Felice C,Marzo M,Andrisani G,Fiorino G,Sociale O,Papa A,De Vitis I,Rapaccini GL,Guidi L

更新日期：2013-04-01 00:00:00

abstract：BACKGROUND:The hygiene hypothesis suggests an inverse relationship between the incidence of parasitic infections and chronic inflammatory bowel diseases (IBD). We investigated the therapeutic potential of Schistosoma mansoni and Ancylostoma caninum soluble proteins on experimental colitis in mice. METHODS:Colitis was ...

journal_title：Inflammatory bowel diseases

authors： Ruyssers NE,De Winter BY,De Man JG,Loukas A,Pearson MS,Weinstock JV,Van den Bossche RM,Martinet W,Pelckmans PA,Moreels TG

更新日期：2009-04-01 00:00:00

abstract：BACKGROUND:To explore the relationship between personality and disease-specific quality of life [Inflammatory Bowel Disease Questionnaire (IBDQ)] in distressed [Perceived Stress Questionnaire (PSQ)] patients with ulcerative colitis (UC) and Crohn's disease (CD). METHODS:Included in the study were 56 patients with UC a...

journal_title：Inflammatory bowel diseases

authors： Boye B,Jahnsen J,Mokleby K,Leganger S,Jantschek G,Jantschek I,Kunzendorf S,Benninghoven D,Wilhelmsen I,Sharpe M,Blomhoff S,Malt UF,Lundin KE

更新日期：2008-05-01 00:00:00

abstract：BACKGROUND:The dinitrofluorobenzene/dinitrosulfonic acid (DNFB/DNS) model was originally described as an experimental model of intestinal inflammation resembling human ulcerative colitis (UC). Due to the absence of acceptable UC experimental models for pharmacological preclinical assays, here we examine the immune resp...

journal_title：Inflammatory bowel diseases

authors： Bailón E,Cueto-Sola M,Utrilla P,Nieto A,Garrido-Mesa N,Celada A,Zarzuelo A,Xaus J,Gálvez J,Comalada M

更新日期：2011-10-01 00:00:00

abstract：:Crohn's disease (CD) leads to the development of complications through progressive uncontrolled inflammation and the transmural involvement of the bowel wall. Most of the available literature on penetrating CD focuses on the perianal phenotype. The management of nonperianal penetrating complications poses its own set ...

journal_title：Inflammatory bowel diseases

authors： Hirten RP,Shah S,Sachar DB,Colombel JF

更新日期：2018-03-19 00:00:00

abstract：BACKGROUND:Severe mucosal tissue damage requiring efficient wound healing is a main feature of inflammatory bowel disease but excessive tissue repair promotes fibrosis. The clinical investigation of fibrosis is confined to the limited amount of biological material available from patients. This makes the establishment o...

journal_title：Inflammatory bowel diseases

authors： Hausmann M,Rechsteiner T,Caj M,Benden C,Fried M,Boehler A,Rogler G

更新日期：2013-10-01 00:00:00

abstract：BACKGROUND:There has been a dramatic increase in investigations on the potential mechanistic role of the intestinal microbiota in various diseases and factors modulating intestinal microbial composition. We recently reported on intestinal microbial shifts after smoking cessation in humans. In this study, we aimed to co...

journal_title：Inflammatory bowel diseases

authors： Biedermann L,Brülisauer K,Zeitz J,Frei P,Scharl M,Vavricka SR,Fried M,Loessner MJ,Rogler G,Schuppler M

更新日期：2014-09-01 00:00:00

abstract：:Nephrotoxicity has been described in some patients with inflammatory bowel disease (IBD) treated with 5-aminosalicylic acid (5-ASA). Studies with 5-ASA treatment in which serum creatinine or creatinine clearance was measured regularly show that nephrotoxicity is exceptional (mean rate of only 0.26% per patient-year). ...

journal_title：Inflammatory bowel diseases

authors： Gisbert JP,González-Lama Y,Maté J

更新日期：2007-05-01 00:00:00

abstract：BACKGROUND:Microbiota is most likely essential in the pathogenesis of Crohn's disease (CD). Fecal diversion after ileocecal resection (ICR) protects against CD recurrence, whereas infusion of fecal content triggers inflammation. After ICR, the majority of patients experience endoscopic recurrence in the neoterminal ile...

journal_title：Inflammatory bowel diseases

authors： Olaisen M,Flatberg A,Granlund AVB,Røyset ES,Martinsen TC,Sandvik AK,Fossmark R

更新日期：2021-01-01 00:00:00

abstract：BACKGROUND:Inflammatory bowel disease (IBD)-associated dysbiosis is characterized by a loss of Faecalibacterium prausnitzii, whose supernatant exerts an anti-inflammatory effect. However, the anti-inflammatory substances in F. prausnitzii supernatant and the mechanism in ameliorating colitis in IBD have not yet been fu...

journal_title：Inflammatory bowel diseases

authors： Zhou L,Zhang M,Wang Y,Dorfman RG,Liu H,Yu T,Chen X,Tang D,Xu L,Yin Y,Pan Y,Zhou Q,Zhou Y,Yu C

更新日期：2018-08-16 00:00:00

abstract：INTRODUCTION:The incidence of early-onset CD in Scotland is among the highest worldwide. Three single nucleotide polymorphisms (SNPs) R702W, G908R and Leu1007finsC in the NOD2/CARD15 gene predispose to adult CD. We investigated the contribution of these variants to disease susceptibility and phenotype in the Scottish e...

journal_title：Inflammatory bowel diseases

authors： Russell RK,Drummond HE,Nimmo EE,Anderson N,Smith L,Wilson DC,Gillett PM,McGrogan P,Hassan K,Weaver LT,Bisset M,Mahdi G,Satsangi J

更新日期：2005-11-01 00:00:00

abstract：BACKGROUND:The proinflammatory effect of high-fat diet has been observed beyond the cardiovascular system, but there is little evidence to support its role in triggering inflammatory bowel disease. GPx1/2-double-knockout (DKO) mice deficient in 2 intracellular glutathione peroxidases, GPx1 and GPx2, on a C57BL/6 (B6) b...

journal_title：Inflammatory bowel diseases

authors： Gao Q,Esworthy RS,Kim BW,Synold TW,Smith DD,Chu FF

更新日期：2010-12-01 00:00:00

abstract：BACKGROUND:The consistency of endoscopic and histologic findings in patients with ulcerative colitis (UC) has not been elucidated. Choice of assessment may affect study outcomes. METHODS:Post hoc analyses were performed using data from 2 randomized, controlled multicenter trials: (1) SAG-26, mesalazine granules for in...

journal_title：Inflammatory bowel diseases

authors： Wolff S,Terheggen G,Mueller R,Greinwald R,Franklin J,Kruis W

更新日期：2013-11-01 00:00:00

abstract：:Inflammatory bowel disease (IBD) is a chronic remitting disorder with increasing incidence worldwide. The intestinal epithelial barrier plays a major role in IBD, contributing to its pathogenesis, evolution, and perpetuation over time. Until recently, studies focused on exploring the role of the intestinal epithelium ...

journal_title：Inflammatory bowel diseases

authors： Dotti I,Salas A

更新日期：2018-11-29 00:00:00

abstract：BACKGROUND:In our clinical practice, women often report excess weight gain with infliximab (IFX) use. There are currently no studies investigating weight gain after antitumor necrosis factor therapy in patients with inflammatory bowel disease. The objective of this study was to evaluate the association of clinical fact...

journal_title：Inflammatory bowel diseases

authors： Christian KE,Russman KM,Rajan DP,Barr EA,Cross RK

更新日期：2020-01-01 00:00:00

abstract：Background:Colorectal cancer (CRC) is a major cause of cancer-related deaths, and tumor-related comorbidities additionally lower life quality and survival. Mutations in the tumor suppressor adenomatous polyposis coli (APC) are associated with sporadic CRC and familial adenomatous polyposis (FAP), which results in the g...

journal_title：Inflammatory bowel diseases

authors： Saul D,Schilling AF,Kosinsky RL

更新日期：2018-10-12 00:00:00

abstract：:This review covers the use of steroids in the treatment of both ulcerative colitis and Crohn's disease. It looks at controlled trials and uncontrolled trials as to the benefits of this agent in both inducing and maintaining remission. The review also stresses the high incidence of toxicity with prolonged use of steroi...

journal_title：Inflammatory bowel diseases

authors： Present DH

更新日期：2000-02-01 00:00:00

abstract：BACKGROUND:The incorporation of abstracts from scientific meetings into systematic reviews and practice guidelines may reduce publication bias and delays in implementing therapeutic interventions. METHODS:All abstracts of Phase III randomized controlled trials in inflammatory bowel disease accepted at Digestive Diseas...

journal_title：Inflammatory bowel diseases

authors： Kottachchi D,Nguyen GC

更新日期：2010-06-01 00:00:00

abstract：BACKGROUND:Our objectives were to assess the differences in perforating disease behavior, disease severity, and extraintestinal manifestations (EIM) in patients with Crohn's disease (CD) by race. MATERIALS AND METHODS:We identified outpatients with CD evaluated at the University of Maryland Gastroenterology Faculty Pr...

journal_title：Inflammatory bowel diseases

authors： Cross RK,Jung C,Wasan S,Joshi G,Sawyer R,Roghmann MC

更新日期：2006-03-01 00:00:00

abstract：BACKGROUND:The purpose of the study was to determine the role of fecal calprotectin and lactoferrin in the prediction of inflammatory bowel disease relapses, both in patients with ulcerative colitis (UC) and Crohn's disease (CD), in a large, long-term, follow-up study. METHODS:The prospective multicenter study include...

journal_title：Inflammatory bowel diseases

authors： Gisbert JP,Bermejo F,Pérez-Calle JL,Taxonera C,Vera I,McNicholl AG,Algaba A,López P,López-Palacios N,Calvo M,González-Lama Y,Carneros JA,Velasco M,Maté J

更新日期：2009-08-01 00:00:00

abstract：BACKGROUND:The efficacy of anti-tumor necrosis factor monoclonal antibody (anti-TNF mAb) for Crohn's disease (CD) is well established, and anti-interleukin-6 receptor (anti-IL-6R) mAb has also been reported to be effective in CD. It is, however, unclear if the efficacy and mechanisms of both agents are different in CD ...

journal_title：Inflammatory bowel diseases

authors： Terabe F,Fujimoto M,Serada S,Shinzaki S,Iijima H,Tsujii M,Hayashi N,Nomura S,Kawahata H,Jang MH,Miyasaka M,Mihara M,Ohsugi Y,Kishimoto T,Naka T

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Many treatment options exist for children with inflammatory bowel disease (IBD), yet the lack of clinical guidelines for management has lead to great variation in care. The purpose of this project was to evaluate current treatment modalities in children from the Northeast US who applied to the 2010 session o...

journal_title：Inflammatory bowel diseases

authors： Rosen D,Kathy-Hoffstadter-Thal,Bao R,Tomaino J,Ceballos C,Russell GJ,Benkov KJ

更新日期：2012-10-01 00:00:00

abstract：BACKGROUND:As the American population is aging, the number of older people with inflammatory bowel disease is increasing. We used clinical data from the Sinai-Helmsley Alliance for Research Excellence (SHARE), a prospective cohort, to examine disease and treatment differences in older adults. METHODS:We performed a cr...

journal_title：Inflammatory bowel diseases

authors： Kochar B,Long MD,Galanko J,Raffals LE,Ananthakrishnan A,Sandler RS

更新日期：2017-07-01 00:00:00

abstract：BACKGROUND:Individuals with ulcerative colitis are at high risk of developing colitis-associated cancer. 5-Aminosalicylate (5-ASA) protects from cancer by its antiinflammatory activity as well as by altering cell growth, inducing apoptosis, and reducing replication errors. So far neither 5-ASA's structural specificity ...

journal_title：Inflammatory bowel diseases

authors： Campregher C,Luciani MG,Biesenbach P,Evstatiev R,Lyakhovich A,Gasche C

更新日期：2010-04-01 00:00:00

abstract：BACKGROUND:Infliximab is an effective therapy for inflammatory bowel disease (IBD). However, more than 50% of patients lose response. Empiric dose intensification is not effective for all patients because not all patients have objective disease activity or subtherapeutic drug level. The aim was to determine how an obje...

journal_title：Inflammatory bowel diseases

authors： Huang VW,Prosser C,Kroeker KI,Wang H,Shalapay C,Dhami N,Fedorak DK,Halloran B,Dieleman LA,Goodman KJ,Fedorak RN

更新日期：2015-06-01 00:00:00